Loading organizations...

§ Private Profile · La Jolla, CA, USA
Biopharmaceutical company developing treatments for diabetic complications: neuropathy, nephropathy, retinopathy. Lead product Ersatta.
Based in La Jolla, California, Cebix was a venture-funded biopharmaceutical company that developed specialized treatments for severe diabetic complications, specifically targeting neuropathy, nephropathy, and retinopathy. The organization's lead clinical product, Ersatta, functioned as a proprietary pegylated synthetic human C-peptide designed to replace deficient peptides in patients suffering from type 1 diabetes complications. Before permanently ceasing operations in February 2015 after determining that further clinical development was no longer viable, the enterprise secured $30.9 million in private Series B equity financing, accumulated a portfolio of 33 patents, and scaled to a peak headcount of 51 employees worldwide. The executive team was guided by Chief Executive Officer Joel Martin, who brought prior leadership experience from recognizable industry entities including Forward Ventures, Altair Therapeutics, and Quantum Dot Corp. Cebix was officially founded in 2008 by medical researcher John Wahren.
Cebix has raised $52.0M across 3 funding rounds.
Cebix has raised $52.0M in total across 3 funding rounds.
Cebix is (or was) a small biotech company that developed ERSATTA, a C‑peptide replacement therapy aimed at treating long‑term complications of diabetes such as neuropathy, nephropathy and retinopathy[2][6]. The company operated out of La Jolla / San Diego and ran early clinical trials (Phase 1/1b–1/2) and raised multiple venture financings before winding down operations around 2015[2][3].
High‑Level Overview
Origin Story
Core Differentiators
Role in the Broader Tech/Health Landscape
Quick Take & Future Outlook
Sources used: company and press coverage summarizing Cebix’s ERSATTA program, clinical progress and financings, and reporting on the company’s wind‑down[2][3][6][7].
Cebix has raised $52.0M across 3 funding rounds. Most recently, it raised $33.0M Series B in October 2012.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Oct 1, 2012 | $33M Series B | — | ARCH Venture Partners, Canaan Partners, Sofinnova Investments, Interwest Partners, Thomas, McNerney & Partners | Announced |
| Aug 1, 2010 | $16M Series U | — | ARCH Venture Partners, Canaan Partners, Sofinnova Investments | Announced |
| Oct 1, 2008 | $3M Series A | — | Canaan Partners, Sofinnova Investments | Announced |
Cebix has raised $52.0M in total across 3 funding rounds.
Cebix's investors include ARCH Venture Partners, Canaan Partners, Sofinnova Investments, InterWest Partners, Thomas, McNerney & Partners.